Less than a year after its introduction in Europe, Celltrion’s Remsima SC subcutaneous infliximab biosimilar has captured material market share among inflammatory bowel disease patients in the EU5 countries, including the UK, according to a newly-released report sampling nearly 250 EU5 gastroenterologists in November and December last year.
Aided by the cannibalization of the intravenous formulation of Remsima – a biosimilar to Janssen’s Remicade – and the decline...






